摘要
目的:探讨单味黄芪及其复方黄芪制剂对大鼠慢性萎缩性胃炎(GAG)的疗效及作用机制.方法:将Wistar大鼠80只(雌雄各半)随机分为正常对照组(n=12),给予普通饲料,正常饮水;模型组(n=68),采用综合造模法行CAG模型制备.23 wk后将成功复制的CAG大鼠随机分为模型对照组,黄芪单药2.5 kg/L组,黄芪复方3.45 kg/L组,1.10 kg/L组,0.35 kg/L组(n=8),叶酸治疗组(n=9).药物干预7 wk后,HE染色并在光镜下观察各组大鼠的胃黏膜病理组织学改变;采用Elasia法检测全部存活大鼠的增殖细胞核抗原(PCNA)、凋亡抑制基因B细胞淋巴瘤/白血病-2(BCL-2)、白细胞介素-4(IL4)、干扰素-γ(IFN-γ)及转化生长因子-β1(TGF-β1),计数并作定量分析.结果:与正常对照组相比较,模型组PCNA(153.08±38.67),BCL-2(124.90 4±20.79),IFN-γ(27.99±5.57),TGF-β1(228.97±79.50)上调(P<0.05).与模型组相比较,黄苠单药2.5 ks/L组PCNA及BCL-2分别为(48.83±12.45)(73.05 4±20.22)与黄芪复方3.45 ks/L组(101.18±31.88),(97.72 4±25.34);1.10 ks/L组(69.03±13.91),(78.35 4±15.95);0.35 kg/L组(72.32±19.15),(84.58 4±19.66)相比较下降(P<0.05).黄芪单药2.5 kg/L组IFN-γ(15.79±2.68)与黄芪复方1.10 kg/L组(17.04 4±6.92),0.35 ks/L组(17.02±6.35)相比较下降(P<0.05).结论:黄芪及其复方通过调节细胞增殖与凋亡的动态平衡及机体免疫功能治疗大鼠CAG.
Abstract
AIM: To explore the treatment effectiveness and action mechanism of mongolian milkvetch root and its compound on chronic atrophic gastritis(CAG) rats. METHODS: Eighty Wistar rats, half male and half female, were randomized into normal group (n = 12 ) and model group ( n = 68). Nomal group were fed by common diet and free drinking; the CAG model were made by complex method in model group. After 23 weeks, the model were made successfully. Then the model group were randomized into 6 groups: model group ( n = 8 ) , single mongolian milkvetch root group (n = 8) , high-dose combined group ( n = 8) , middle-dose combined group ( n = 8 ) , low-dose conbined group ( n = 8 ) and folic acid treating group. All treatment groups were treated for 7 weeks. All rats were observed in their histopathological changes under a light microscope with HE staining and detected proliferating cell nuclear antigen ( PCNA ) , B-cell leukemia/lymphoma-2 ( BCL-2 ) , Interleukin-4 ( XL-A ) , interferon gamma ( IFN-γ ) , Transforming growth factor betal ( TGF-01 ) with elasia method. RESULTS: Compared with the normal group, PCNA (153. 08 ± 38.67) ,BCL-2( 124. 90 ±20. 79) , IFN-γ(27. 99 ±5. 57) ,TGF-βl (228. 97 ± 79. 50) of the model group increased(P < 0. 05); compared with the model group, PCNA and BCL-2 of the the single mongolian milkvetch root group (48. 83 ± 12.45), (73.05 ± 20. 22), high-dose combined group (101. 18 ± 31. 88), ( 97. 72 ± 25. 34), middle-dose combined group(69. 03 ± 13. 91), (78. 35 ± 15. 95) , low-dose conbined group (72. 32 ± 19. 15 ) , ( 84. 58 ± 19.66 ) decreased (P <0.05); IFN-γ of the single mongolian milkvetch root group( 15.79 ± 2. 68 ) , middle-dose combined group ( 17. 04 ± 6. 92 ) ,low-dose conbined group (17. 02 ± 6. 35) decreased ( P < 0. 05 ). CONCLUSION: Mongolian milkvetch root and its compound by regulating cell proliferation and apoptosis of dynamic equilibrium and the treatment of immune function in rats with chronic atrophic gastritis.
NETL
NSTL
维普
万方数据